Wednesday 14 September 2022

Technologies and GxP considerations for vaccine development


Messenger RNA (mRNA) vaccines made global headlines in 2021 in the fight against the SARS-CoV-2 virus responsible for COVID-19 (through the Pfizer-BioNTech and the Moderna vaccines). The principle behind these vaccines is to use engineered mRNA to provide instructions to cells to signal the immune system to create antibodies against specific viral pathogens of concern. 



mRNA vaccines against the coronavirus are not the only biotechnological products in the pipeline. Other genetic immunogens mRNA vaccines have been subject to research for several years, including those intended to act against viruses and viral diseases like influenza, cytomegalovirus (a herpes related virus), dengue fever, Zika, and rabies and against malaria parasites. Current research is also looking at the use of RNA vaccines for certain forms of cancer (immunotherapy).


Investment in new vaccines is high. This article assesses the developmental landscape for vaccines and considers the types of diseases that this area of vaccinology can be used to combat.


The reference is:


Sandle, T. (2022) Technologies and GxP considerations for vaccine development, Pharma Machines and Technology, 16 (6): 18-28


The article can be accessed here:


Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (

No comments:

Post a Comment

Pharmaceutical Microbiology Resources

Special offers